We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current XFOR market cap is 81.35M. The company's latest EPS is USD -0.5932 and P/E is -0.78.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 563k | 560k |
| Operating Income | -27.21M | -25.2M | -37.29M | -33.9M | -34.5M |
| Net Income | -2.31M | -19.13M | -51.77M | 90.83M | -36.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 3M | 0 | 0 | 0 |
| Operating Income | -47.8M | -59.87M | -85.11M | -88.08M | -107.52M |
| Net Income | -53.4M | -62.13M | -102.64M | -96.41M | -101.17M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 173.29M | 147.26M | 112.18M | 210.61M | 178.17M |
| Total Liabilities | 105.7M | 96.16M | 111.15M | 116.16M | 118.54M |
| Total Equity | 67.59M | 51.1M | 1.04M | 94.45M | 59.62M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 160.7M | 122.87M | 117.18M | 155.59M | 147.26M |
| Total Liabilities | 31.48M | 50.07M | 52.76M | 81.54M | 96.16M |
| Total Equity | 129.22M | 72.8M | 64.41M | 74.05M | 51.1M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -68.77M | -96.51M | -33.6M | -63.87M | -97.91M |
| Investing | -10.05M | -14.88M | -5.32M | 98.54M | 75.61M |
| Financing | 88.42M | 88.52M | N/A | 20.16M | 20.16M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -48.06M | -58.82M | -70.91M | -77.1M | -96.51M |
| Investing | 27.23M | -1.36M | -615k | -103k | -14.88M |
| Financing | 140.66M | 12.39M | 74.25M | 117.23M | 88.52M |
| Market Cap | 81.35M |
| Price to Earnings Ratio | -0.78 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.79 |
| Price to Book Ratio | 1.54 |
| Dividend Yield | - |
| Shares Outstanding | 170.55M |
| Average Volume (1 week) | 4.67M |
| Average Volume (1 Month) | 3M |
| 52 Week Change | -42.44% |
| 52 Week High | 1.60 |
| 52 Week Low | 0.2612 |
| Spread (Intraday) | 0.02 (3.24%) |
| Company Name | X4 Pharmaceuticals Inc |
| Address |
3411 silverside road tatnall wilmington, delaware 19810 |
| Website | https://www.x4pharma.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
